Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:GMDA NASDAQ:GNFT NASDAQ:LOGC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$18.51+0.2%$19.68$10.21▼$25.67$4.41B0.433.68 million shs1.95 million shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsGNFTGENFIT$3.65-2.7%$4.12$2.55▼$6.42$187.51M1.0810,427 shs5,487 shsLOGCLogicBio Therapeutics$7.27-2.9%$2.06$0.26▼$3.77$191.06M2.06168,718 shs91,424 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+0.71%+0.96%-11.46%-4.79%+53.92%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%GNFTGENFIT+1.19%-1.83%-11.43%+10.62%-14.05%LOGCLogicBio Therapeutics+1.77%+3.31%+3.74%+11.46%+30.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics3.9697 of 5 stars3.71.00.00.03.12.53.1GMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/AGNFTGENFIT2.4494 of 5 stars3.55.00.00.02.10.00.0LOGCLogicBio Therapeutics1.7154 of 5 stars0.05.00.04.70.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6749.47% UpsideGMDAGamida Cell 0.00N/AN/AN/AGNFTGENFIT 3.00Buy$13.00256.16% UpsideLOGCLogicBio Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ADMA, LOGC, GMDA, and GNFT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ADMAADMA BiologicsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M10.36$0.54 per share34.12$1.48 per share12.51GMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00GNFTGENFIT$76.77M2.38$0.07 per share53.61$1.50 per share2.43LOGCLogicBio Therapeutics$287M0.67N/AN/A$8.96 per share0.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8532.9826.83N/A45.01%47.16%30.51%8/6/2025 (Estimated)GMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/AGNFTGENFIT$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)LOGCLogicBio Therapeutics-$317M-$5.79N/A∞N/A-141.03%-81.98%-52.13%N/ALatest ADMA, LOGC, GMDA, and GNFT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025LOGCLogicBio TherapeuticsN/A-$0.27N/A-$0.27N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/AGNFTGENFITN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36GMDAGamida Cell213.142.162.09GNFTGENFIT0.081.231.23LOGCLogicBio TherapeuticsN/A31.6031.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%GMDAGamida Cell50.34%GNFTGENFIT2.24%LOGCLogicBio Therapeutics46.05%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%GMDAGamida Cell3.40%GNFTGENFIT4.20%LOGCLogicBio Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million230.38 millionOptionableGMDAGamida Cell143154.05 million143.70 millionOptionableGNFTGENFIT12050.00 million47.90 millionNot OptionableLOGCLogicBio Therapeutics6226.28 million24.16 millionOptionableADMA, LOGC, GMDA, and GNFT HeadlinesRecent News About These CompaniesContextLogic Announces Adjournment of Annual Meeting of Stockholders to Allow Additional Time for Stockholders to Vote “FOR” the Reorganization ProposalJuly 10 at 1:20 PM | globenewswire.comContextLogic Appoints Finance Executive Michael Scarola as New Chief Financial OfficerJune 25, 2025 | globenewswire.comContextLogic Stock Price, Quotes and Forecasts | NASDAQ:LOGC | BenzingaJune 2, 2025 | benzinga.comContextLogic Inc. to Commence Trading on the OTC Markets and Delist from NasdaqMay 30, 2025 | globenewswire.comContextLogic Inc. (LOGC) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comContextLogic Inc. Reports First-Quarter 2025 Financial ResultsMay 9, 2025 | globenewswire.comContextLogic to Announce First Quarter 2025 Results on May 9, 2025May 6, 2025 | globenewswire.comContextLogic Inc. Reports Fourth-Quarter and Fiscal Year 2024 Financial ResultsMarch 12, 2025 | globenewswire.comContextLogic to Announce Fourth Quarter and Full Year 2024 Results and Provide Strategic Update on March 12, 2025March 10, 2025 | globenewswire.comLOGC stock touches 52-week high at $8.24 amid market optimismFebruary 13, 2025 | msn.comContextLogic Inc. Reports Third-Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comAstraZeneca pays record 660% premium for gene editing company LogicBioSeptember 22, 2024 | pharmaphorum.comPLGCB Linkage Global IncSeptember 15, 2024 | seekingalpha.comContextLogic Inc. Reports Second-Quarter Financial ResultsAugust 8, 2024 | globenewswire.comLogicBio Therapeutics, Inc. (LOGC)May 14, 2024 | finance.yahoo.comRVVTF Revive Therapeutics Ltd.March 27, 2024 | seekingalpha.comLogicBio's IPO: What You Need To KnowSeptember 24, 2023 | finance.yahoo.comRare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports LtdMarch 31, 2023 | uk.finance.yahoo.comAlexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® TherapeuticsNovember 16, 2022 | finance.yahoo.comLogicBio Therapeutics, Inc.: LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesNovember 14, 2022 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADMA, LOGC, GMDA, and GNFT Company DescriptionsADMA Biologics NASDAQ:ADMA$18.51 +0.04 (+0.22%) Closing price 04:00 PM EasternExtended Trading$18.36 -0.16 (-0.84%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Gamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.GENFIT NASDAQ:GNFT$3.65 -0.10 (-2.67%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.LogicBio Therapeutics NASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
